Vaxcyte (PCVX)
(Real Time Quote from BATS)
$84.04 USD
+2.41 (2.95%)
Updated Jul 22, 2024 02:50 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PCVX 84.04 +2.41(2.95%)
Will PCVX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PCVX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCVX
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte
PCVX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Vaxcyte (PCVX) Might Surprise This Earnings Season
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up
Other News for PCVX
Russell rotation: YTD market capitalizations swelling for small-caps
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Vaxcyte Appoints John Furey to Board of Directors
Buy Rating on Vaxcyte (PCVX) Stock: Serotype Coverage and Expanding Vaccine Recommendations Fuel Optimism
Buy Rating Affirmed for Vaxcyte Amid Promising Vaccine Developments and Market Potential